Letter to the EditorPneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: Report of 11 cases and review of the literature
Section snippets
Conflict of interest statement
The authors report no relationships that could be construed as a conflict of interest.
Acknowledgment
We thank C. Cassius, T. Legris, M. Le Besnerais, AS. Morin, and A. Mekinian for their help to collect clinical data.
References (10)
- et al.
Pneumocystis pneumonia in patients treated with rituximab
Chest J
(1 juill 2013) - et al.
The changing trends and profile of pneumocystosis mortality in the United States, 1999–2014
Mycoses
(2017) - et al.
B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection
J Immunol
(2006) - et al.
Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease
Rheumatology (Oxford)
(2015) - et al.
Should Pneumocystis jirovecii prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?
Clin Rheumatol
(nov 2013)
There are more references available in the full text version of this article.
Cited by (14)
Use of rituximab in maintenance treatment of pemphigus: A retrospective series
2020, Annales de Dermatologie et de VenereologieHigh prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis
2023, Rheumatology (United Kingdom)Risk factors of Pneumocystis carinii pneumonia in childhood‑onset systemic lupus erythematosus
2022, Zhonghua er ke za zhi / Chinese Journal of PediatricsPulmonary Infiltrates
2022, Infectious Complications in Biologic and Targeted Therapies
© 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.